Significant performance increase of API and preparation enterprises

[China Pharmaceutical network industry trends 】At present, affected by low added value and environmental protection pressure, China's API industry has been in a downturn for many years In this context, the pattern of API industry has been restructured, and small and medium-sized API enterprises with low environmental protection standards have been expelled from the market Many enterprises with environmental protection strength are making strategic transformation from API to preparation, such as adopting the strategy of "two wheel drive of API and preparation" in the original Under the premise of continuous production of raw materials and drugs, accelerate the production of preparations, and intend to expand export channels It is reported that the strategic planning direction of minoua pharmaceutical industry is the layout of the whole industrial chain of intermediates, APIs and preparations, especially in the field of APIs and intermediates In 2018, in view of the shortage of some API varieties, minoua Pharmaceutical Co., Ltd expanded the upstream and downstream of the industrial chain through merger and acquisition of Liaoyuan Pharmaceutical Co., Ltd and equity participation in kerkang minoua The company said that it will focus on expanding the pharmaceutical business, accelerate the industrial upgrading pace of the integration of "intermediates, APIs and preparations" and realize the dual drive strategy of APIs and preparations through the strategy of simultaneous endogenous growth and extension expansion, while expanding and strengthening the existing main business "We have the advantages of API varieties After the expansion of production capacity, we can guarantee the supply of API in the future This is the basis for the development of the company's preparations in the future The bottleneck that many preparation enterprises are facing now is actually the problem of API." Sun Yan, Secretary of the board of directors of the company, once said so According to the preliminary calculation by the financial department of minoua pharmaceutical, it is estimated that the net profit attributable to the shareholders of the listed company in 2018 will be 96.5-103 million yuan, an increase of 51.82-58.32 million yuan compared with the same period of last year, a year-on-year increase of 116% - 131% On the evening of March 27, the company released its 2018 annual report, which showed that its operating revenue was 2.428 billion yuan, an increase of 23.13% year on year   For the reason of performance growth, the company said that in the reporting period, in the face of increasingly stringent regulatory environment and market competition pressure in the pharmaceutical industry, on the one hand, the company firmly grasped the market, seized the opportunity, adjusted the sales strategy in a timely manner, expanded product market sales, promoted technological innovation, increased R & D investment, consolidated core competitiveness, improved quality management system, and improved production Product quality, continue to strengthen raw material procurement cost control and production cost assessment, strengthen internal management, and achieved good development performance On the other hand, the company and its subsidiary Jinyao Pharmaceutical Co., Ltd have achieved substantial business integration of API production and preparation production, connected the upstream and downstream industrial chains, and formed a two-wheel linkage development model of raw materials and preparation products The performance driving force is more significant, and the company is expected to usher in greater development in the next few years According to the public information, TIANYAO is mainly engaged in the R & D, production and sales of corticosteroids, amino acid APIs and preparations The company's main products include more than 40 varieties of corticosteroids APIs, 23 varieties of amino acid APIs, and 15 agent-based products such as small volume injection Onlycom Pharma onlycom Pharma is one of the few pharmaceutical enterprises with a relatively complete cephalosporin antibiotic product industry chain in China At present, an integrated business model of pharmaceutical intermediates cephalosporin APIs cephalosporin preparations has been formed It is understood that in recent years, onlycom pharmaceutical has broken through the traditional price competition strategy and expanded to the upstream pharmaceutical intermediate 7-ADCA and the downstream cephalosporin preparation manufacturing It has become one of the few domestic enterprises with a relatively complete cephalosporin antibiotic product industry chain, which can simultaneously engage in the R & D, production and sales of cephalosporin APIs and cephalosporin preparations On October 23, 2018, onlycom pharmaceutical successfully listed on Shenzhen Stock Exchange, ushering in a new development opportunity Its raised investment projects include "the construction project of the production base of 2.17 billion tablets (granules, branches and bags) per year", "the technical transformation project of the production line of cefradine API produced by enzymatic method" and the R & D center According to the industry, the fund-raising investment projects after listing will help enterprises further strengthen the industrial chain, optimize product layout and structure, so as to realize the development strategy of "two wheel drive of APIs and preparations" On February 28, 2019, the 2018 annual performance express released by onlycom pharmaceutical showed that during the reporting period, the company achieved a total operating revenue of 1.255 billion yuan, a year-on-year increase of 43.74%; an operating profit of 131 million yuan, a year-on-year increase of 6.08%; and a total profit of 137 million yuan, a year-on-year increase of 11.15% The main reason for the increase in income in the reporting period is the increase in the price of pharmaceutical products affected by the "two ticket system".